Determinants of newly diagnosed comorbidities among breast cancer survivors (Q44197715)

30 November 2017

title

Determinants of newly diagnosed comorbidities among breast cancer survivors (English)

1 reference

30 November 2017

1 reference

7

Dieter Flesch-Janys

1 reference

30 November 2017

6

Jenny Chang-Claude

1 reference

30 November 2017

4

Alina Vrieling

1 reference

30 November 2017

5

Petra Seibold

1 reference

30 November 2017

3

Judith Heinz

1 reference

30 November 2017

1

Nadia Obi

1 reference

30 November 2017

Daniela Gornyk

2

1 reference

30 November 2017

publication date

26 February 2014

1 reference

Journal of Cancer Survivorship

30 November 2017

published in

1 reference

30 November 2017

volume

8

1 reference

30 November 2017

issue

3

1 reference

30 November 2017

page(s)

384-393

1 reference

Cancer survivors in the United States: age, health, and disability

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

The older cancer survivor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Comorbidity and survival after early breast cancer. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

The influence of comorbidities on overall survival among older women diagnosed with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Association of pre-diagnosis physical activity with recurrence and mortality among women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Body mass index as a predictor of fracture risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Validation of obesity based on self-reported data in Spanish women participants in breast cancer screening programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Validity of self-reported height and weight in 4808 EPIC-Oxford participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Physical activity and risk of cardiovascular disease--a meta-analysis of prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Impact of aromatase inhibitors on bone health in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Cardiotoxic effects of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Cardiovascular effects of systemic cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Meta-analysis of vascular and neoplastic events associated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Prevalence and patterns of morbidity among adults in Germany. Results of the German telephone health interview survey German Health Update (GEDA) 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11764-013-0338-Y

Comparison of interview-based and medical-record based indices of comorbidity among breast cancer patients

21 January 2018

1 reference

12 December 2020

Bone health: osteoporosis, calcium and vitamin D

1 reference

12 December 2020

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

1 reference

12 December 2020

Late Cardiac Mortality and Morbidity in Early-Stage Breast Cancer Patients After Breast-Conservation Treatment

1 reference

12 December 2020

10.1007/S11764-013-0338-Y

Identifiers

DOI

1 reference

30 November 2017

1 reference